Prometheus Laboratories Inc, San Diego, has introduced a therapeutic drug monitoring test for use in adult inflammatory bowel disease patients treated with the biologic Stelara (ustekinumab; UST) by Janssen Biotech.
Prometheus Anser UST enables physicians to monitor the biologic therapy and optimize treatment. Careful monitoring of drug and antidrug antibodies is considered key to optimizing biologic therapy in order to meet the emerging goals of personalized medicine. In clinical practice, measuring drug and antidrug antibody concentrations has already proven effective in adapting treatment strategies in a variety of situations. As a drug-tolerant test, Anser UST measures both serum drug concentrations and antidrug antibody levels from a single serum sample.
Warren Cresswell, Prometheus Laboratories.
“Anser UST joins our expanding portfolio of drug-tolerant therapeutic monitoring tests that help healthcare providers make optimal treatment decisions,” says Warren Cresswell, general manager and head of diagnostics at Prometheus Laboratories. “The addition of Anser UST to our gastrointestinal specialty test portfolio represents the continued commitment to innovation and better patient care that is associated with all Prometheus diagnostics. The Anser portfolio of therapeutic drug monitoring tests now includes tests for infliximab and its biosimilars, adalimumab, vedolizumab, and ustekinumab.”
“The availability of a drug-tolerant assay such as Anser UST represents an important advancement in managing patients with Crohn’s disease,” says William J. Sandborn, MD, chief of the division of gastroenterology and professor of medicine at the University of California, San Diego, School of Medicine. “Crohn’s disease is a complex condition, and optimizing the available therapies is an important part of treatment.”
For more information, visit Prometheus Laboratories.
